Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

394.16 5.94 −1.48%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. (MDGL) revenue by segment, product and region

Revenue by segment $m

Line	FY2025	FY2024
Reportable Segment	958 100.00%	180 100.00%
Revenue	958	180

Gross profit by segment $m, and margin

	FY2025	FY2024
Reportable Segment	‡	‡
Gross profit	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Patients on Rezdiffra	Q3 FY2026	55.9K	29.5K	+89.32%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024
Patients on Rezdiffra	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.